ABSTRACT
Objective To observe the clinical efficacy and safety of Shuxuetong in treatment of paroxysmal atrial fibril-lation in patients with chronic pulmonary heart disease. Methods A randomized single-blinded study was performed. A to-tal of 91 patients with paroxysmal atrial fibrillation and chronic pulmonary heart disease were randomly divided into treat-ment group (n=45) and control group (n=46). The treatment group was received Shuxuetong and clopidogrel treatment for 14 days. The control group was given routine treatment plus clopidogrel 75 mg orally. The average time of cardioversion of parox-ysmal atrial fibrillation was detected within 48 hours. The cardioversion rate of paroxysmal atrial fibrillation and the total effi-ciency were detected after14 days. The serum D-Dimer was detected before and 14 days after treatment . Liver and kidney function and adverse drug reactions were also detected. Results There was no significant difference in average time of car-dioversion of paroxysmal atrial fibrillation in 48 h between two groups (h:12.62±2.32 vs 13.32±2.25,t=1.461). The cardiover-sion rates were 86.67%(39/45) and 82.22%(37/45) at 48 h and 14 d in treatment group, which were significantly higher than those of control group [69.56%(32/46) and 60.87(28/46)]. The D-Dimer at 14 d after treatment was significantly lower in treatment group [(2.05±0.34)mg/L] than before treatment[(2.61±0.27)mg/L], also than that of control group[(2.53±0.31)mg/L]. There were no abnormal liver and kidney function and no adverse reactions between two groups. Conclusion Shuxuetong can significantly prevent the recurrence of paroxysmal atrial fibrillation in patients with chronic pulmonary heart disease, and help to reduce the risk of thromboembolism. It is safe and effective.
